

Original Article

Cite this article: Pokorny T, Duerler P, Seifritz E, Vollenweider FX, Preller KH (2019). LSD acutely impairs working memory, executive functions, and cognitive flexibility, but not risk-based decision-making. *Psychological Medicine* 1–10. <https://doi.org/10.1017/S0033291719002393>

Received: 7 April 2019

Revised: 14 August 2019

Accepted: 17 August 2019


Key words:

5-HT_{2A} receptor; cognition; executive functions; LSD; risk-based decision-making; spatial memory; working memory

Author for correspondence:

Thomas Pokorny, E-mail: thomas.pokorny@bli.uzh.ch

LSD acutely impairs working memory, executive functions, and cognitive flexibility, but not risk-based decision-making

Thomas Pokorny^{1,2} , Patricia Duerler^{1,2}, Erich Seifritz³, Franz X. Vollenweider^{1,2} and Katrin H. Preller^{1,2}

¹Neuropsychopharmacology and Brain Imaging, Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital, University of Zurich, Zurich, Switzerland; ²Hefter Research Center Zurich, Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital, University of Zurich, Zurich, Switzerland and ³Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital, University of Zurich, Zurich, Switzerland

Abstract

Background. Psychiatric and neurodegenerative illnesses are characterized by cognitive impairments, in particular deficits in working memory, decision-making, and executive functions including cognitive flexibility. However, the neuropharmacology of these cognitive functions is poorly understood. The serotonin (5-HT) 2A receptor might be a promising candidate for the modulation of cognitive processes. However, pharmacological studies investigating the role of this receptor system in humans are rare. Recent evidence demonstrates that the effects of Lysergic acid diethylamide (LSD) are mediated via agonistic action at the 5-HT_{2A} receptor. Yet, the effects of LSD on specific cognitive domains using standardized neuropsychological test have not been studied.

Methods. We examined the acute effects of LSD (100 µg) alone and in combination with the 5-HT_{2A} antagonist ketanserin (40 mg) on cognition, employing a double-blind, randomized, placebo-controlled, within-subject design in 25 healthy participants. Executive functions, cognitive flexibility, spatial working memory, and risk-based decision-making were examined by the Intra/Extra-Dimensional shift task (IED), Spatial Working Memory task (SWM), and Cambridge Gambling Task (CGT) of the Cambridge Neuropsychological Test Automated Battery.

Results. Compared to placebo, LSD significantly impaired executive functions, cognitive flexibility, and working memory on the IED and SWM, but did not influence the quality of decision-making and risk taking on the CGT. Pretreatment with the 5-HT_{2A} antagonist ketanserin normalized all LSD-induced cognitive deficits.

Conclusions. The present findings highlight the role of the 5-HT_{2A} receptor system in executive functions and working memory and suggest that specific 5-HT_{2A} antagonists may be relevant for improving cognitive dysfunctions in psychiatric disorders.

Introduction

Most psychiatric and neurodegenerative illnesses are characterized by cognitive impairments (Wunderli *et al.*, 2016; Claesdotter *et al.*, 2018; Jagust, 2018; Wang *et al.*, 2019). These deficits have a deleterious effect on patients' quality of life and are severely impairing real world functioning (Millan *et al.*, 2012). Previous research has described trans-diagnostic impairments in various cognitive domains in patients (Millan *et al.*, 2012). In particular, deficits in executive functions, working memory, and decision-making are among the most common affected domains in psychiatric disorders and have been observed in highly prevalent illnesses like depression, schizophrenia, and substance use disorders (Jessen *et al.*, 2019). While some existing pharmacological treatments have been shown to improve cognitive performance, these effects are small (Désaméricq *et al.*, 2014). Other currently used drugs such as first-generation antipsychotics may even worsen cognitive functions (Hill *et al.*, 2010). Deficits in cognitive abilities are therefore a highly important trans-diagnostic dimension in psychiatric and neurological disorders with a great need for improved treatment (Millan *et al.*, 2012).

Pharmacological studies offer the opportunity to causally investigate the contribution of specific receptors and therefore elucidate the neuropharmacological basis of cognitive deficits. This knowledge is urgently needed for the development of specific and novel treatment approaches. Alterations in serotonin (5-HT) 2A receptor binding has been reported in various psychiatric disorders such as schizophrenia (Talvik-Lotfi *et al.*, 2000), depression (Bhagwagar *et al.*, 2006), and obsessive-compulsive disorder (Perani *et al.*, 2008). Furthermore, this receptor is widely distributed in brain regions important for cognition and learning (Zhang and

Stackman, 2015). However, pharmacological studies investigating the role of this receptor system in humans are rare.

Lysergic acid diethylamide (LSD) is a classical hallucinogenic compound and has been shown to transiently induce subjective psychedelic experiences as well as alterations in brain activity and connectivity via agonistic activity on the 5-HT_{2A} receptor (Preller *et al.*, 2017, 2018a, b). The administration of LSD therefore offers the opportunity to causally elucidate the role of the 5-HT_{2A} receptor in human cognition. Two recent studies reported that LSD subjectively decreased concentration and increased the self-report of cognitive disorganization (Schmid *et al.*, 2015; Carhart-Harris *et al.*, 2016). Yet, objective measures of cognitive abilities under LSD are still lacking. Therefore, the present study investigated the acute effects of LSD on executive functions, spatial working memory, and risk-based decision-making using computerized and standardized tests provided by the Cambridge Neuropsychological Automated Test Battery (CANTAB). Furthermore, while previous studies point to the involvement of the 5-HT_{2A} receptor in LSD-induced effects (Kraehenmann *et al.*, 2017; Preller *et al.*, 2017, 2018b), the contribution of this receptor subtype to alterations in cognitive processes is unknown. To be able to investigate the specific role of the 5-HT_{2A} receptor in cognition, we blocked this receptor subtype via the pre-treatment of LSD with the 5-HT_{2A} receptor antagonist ketanserin. We hypothesized that (1) LSD impairs executive functions, spatial working memory, and risk-based decision-making and (2) that these alterations are attributable to LSD's agonistic activity on the 5-HT_{2A} receptor.

Methods

Participants

Twenty-five healthy participants (19 men, 6 women, mean age \pm SD: 25.24 \pm 2.79, mean verbal IQ \pm SD: 108.4 \pm 9.2) were enrolled in the study. All participants underwent a screening procedure at the Department of Psychiatry, Psychotherapy and Psychosomatic, Psychiatric Hospital, University of Zurich consisting of a psychiatric interview (M.I.N.I., Sheehan *et al.*, 1998), laboratory test (blood chemistry and urinalysis for drug and pregnancy screening), and a routine medical examination including electrocardiogram. Verbal intelligence was measured with the German version of a multiple choice vocabulary intelligence test (Lehrl, 2005). Volunteers were included when they were 20–40 years of age and willing to refrain from consuming psychoactive drugs at least two weeks before the first experimental session and during the study. Drug use during the three months prior to inclusion in the study is shown in Table 1. The exclusion criteria were personal or first-degree relative history of psychiatric disorders, acute or chronic physical illness, cardiovascular diseases, history of head trauma, neurological diseases such as migraine headaches and epilepsy, history of drug dependence or abuse, a previous significant adverse response to a hallucinogenic drug, and pregnancy or lactation. Before participating, all participants gave their written consent after having received detailed written and oral information about the aims of the study, and the effects and possible risks of the substances administered in accordance with the Declaration of Helsinki. The study was approved by the Ethics Committee of the Department of Public Health of the Canton of Zurich, Switzerland, and the use of LSD was authorized by the Swiss Federal Office for Public Health, Department of Pharmacology and Narcotics, Berne, Switzerland. The current

Table 1. Drug use in the last 3 months prior to study inclusion in the study sample ($n = 25$)

Drug	Number of subjects	Mean (SD) number of uses
THC	8	9.75 (12.16)
MDMA	2	1 (0)
Psilocybin	2	1.5 (0.71)
LSD	3	1 (0)
DMT	1	1
LSA	1	1

THC, tetrahydrocannabinol; MDMA, 3,4-methylenedioxymethamphetamine; LSD, lysergic acid diethylamide; DMT, *N,N*-dimethyltryptamine; LSA, d-lysergic acid amide.

data were collected as part of a larger study (Kraehenmann *et al.*, 2017; Preller *et al.*, 2017, 2018b) and the study was registered at clinicaltrials.gov (NCT02451072).

Study design and experimental procedures

This study employed a double-blind, randomized, placebo-controlled, within-subject design with three experimental sessions, each separated by at least two weeks. All participants underwent three drug conditions: placebo + placebo (Pla), placebo + LSD (LSD), and ketanserin + LSD (Ket + LSD). One hour after the intake of the first capsule (placebo: 179 mg mannitol, 1 mg aerosil, p.o.; or ketanserin: 40 mg, p.o.) the second one (placebo: 179 mg mannitol, 1 mg aerosil, p.o.; or LSD: 100 μ g, p.o.) was administered. All substances were filled in identical looking gelatine capsules. A urine test for drug-screening and pregnancy-test was conducted at the beginning of each experimental session before drug administration. Participants completed the Intra/Extra-Dimensional shift task (IED), Spatial Working Memory task (SWM), and Cambridge Gambling Task (GCT, CANTABclipse 5.0.12, Cambridge Cognition Ltd., Cambridge, UK) on a computer with a 18" touch-sensitive screen (Elo Touch Solutions) in a quiet room 220 min after the administration of the second capsule. Task order was the same for all participants and sessions. Total time required to complete the three tasks was approximately 25 min. Participants completed the Five Dimension Altered State of Consciousness (5D-ASC) questionnaire (Dittrich, 1998) 720 min after the second drug intake to retrospectively rate subjective drug effects.

Questionnaire and cognitive tasks

Altered States of Consciousness Rating Scale

The 5D-ASC (Dittrich, 1998) was used to assess subjective drug effects in each session. Scores were calculated for eleven validated subscales (Studerus *et al.*, 2010): experience of unity, spiritual experience, blissful state, insightfulness, disembodiment, impaired control and cognition, anxiety, complex imagery, elementary imagery, audio-visual synesthesia, and changed meaning of percepts. Results of the 5D-ASC data are expressed as percentage scores of maximum absolute subscale values.

Executive functions: Intra/Extra-Dimensional shift task

The IED is a test of rule acquisition and cognitive shifting and represents a computerized analog of the Wisconsin Card Sorting test. Besides attentional set-shifting the task measures

different cognitive abilities such as discriminative learning, reversal learning, formation of an attentional set, shifting of attention within the same dimension (intra-dimensional shift, IDS) and between different perceptual dimensions (extra-dimensional shift, EDS) (Owen *et al.*, 1991; Pantelis *et al.*, 2009). Perceptual dimensions are operationalized via two stimulus characteristics (purple-filled shapes or white lines). Attentional set-shifting is a measure of cognitive flexibility and executive functions. The task consists of nine learning stages, during which the participant first has to focus on shapes or lines within a relevant dimension (IDS) and then shift attention to a previously irrelevant dimension (EDS, stage 8, for a detailed description see Pantelis *et al.*, 2009). The measures of performance on this task are: number of stages completed (stages completed), total number of errors made across all stages adjusted for stages not completed (number of errors adjusted) representing a measure of subject's efficiency in attempting the test, the number of errors on individual stages (number of errors), and the mean time to reach a decision within individual stages (total latency). While the orbitofrontal cortex and the posterior parietal cortex have been shown to be more involved during the reversal stages of the IED, the ventrolateral prefrontal cortex (PFC) selectively governs attentional set-shifting (EDS stage) (Dias *et al.*, 1996; Hampshire and Owen, 2006; Owen *et al.*, 1993).

Working memory: Spatial Working Memory task

The SWM is a self-paced task during which an increasing number of boxes (four, six, and eight) is presented in four trials on the screen. Participants are supposed to find blue tokens which are hidden inside the boxes by touching the boxes and thereby opening them. In each trial, the same number of tokens has to be found as the number of boxes presented on the screen. Participants are informed that once a token has been found within a particular box, the box will not be used again to hide a token. This tests measures executive functions (strategy score) as well as working memory errors (between and within errors). Between errors occur when a participant revisited a box in which a token had previously been found, whereas within errors are the number of times a participant revisited a box already found to be empty during the same search sequence. Strategy score describes the use of an efficient search strategy by beginning with a particular box and then returning to that box when a blue token was found to start the new search sequence. High strategy scores represent poor use of a strategy. Performance of the SWM relies on frontal lobe integrity (Owen *et al.*, 1990, 1995, 1996).

Risk-based decision-making: Cambridge Gambling Task

The CGT assesses decision-making and risk-taking behavior outside a learning context. Participants start the task with 100 points. They are presented with 10 boxes on the screen. The boxes are either red or blue. The ratio of red and blue boxes varies across trials (9:1, 8:2, 7:3, 6:4, 5:5). Participants have to decide whether a randomly hidden token is more likely to be in a red or blue box. Subsequently, participants bet on their decision by selecting a proportion of their points. The proportion of points (5%, 25%, 50%, 75%, 95%) that can be selected are presented in either ascending or descending order. The outcome measures of this task are: the proportion of trials on which subjects chose the more likely outcome (quality of decision-making), the proportion of current points that the subject stakes on each gamble when the more likely outcome is selected (risk taking), and deliberation

time (mean latency from presentation of the colored boxes to subject's choice of which color to bet on). The CGT has been shown to be sensitive to the manipulation of the serotonergic system in particular in orbital prefrontal regions (Rogers *et al.*, 1999). Furthermore risk adjustment assessed with the CGT relies on integrity of the ventromedial PCF and the insula (Clark *et al.*, 2008).

Statistical analysis

Data were analyzed using STATISTICA 8.0 for Windows (StatSoft). For 5D-ASC ratings, a repeated-measures ANOVA with drug (Pla, LSD, Ket + LSD) and subscale (experience of unity, spiritual experience, blissful state, insightfulness, disembodiment, impaired control and cognition, anxiety, complex imagery, elementary imagery, audio-visual synesthesia, changed meaning of percepts) as within-subject factors were computed. For CANTAB outcome variables (IED: number of errors adjusted, numbers of errors, and total latency; SWM: between errors, within errors, and strategy; CGT: quality of decision-making, risk taking, and deliberation time) repeated-measures ANOVAs with drug (Pla, LSD, Ket + LSD) as within-subject factor was computed. For the IED stage (1–9) was introduced as an additional within-subject factor. For the SWM, stage (4, 6, 8 boxes) was introduced as additional within-subject factor. For the CGT risk ratio (9:1, 8:2, 7:3, 6:4) was introduced as additional within-subject factors. Tukey post-hoc comparisons followed significant main effects or interactions. Further, multiple linear regression analyses using the enter method were calculated to predict significant LSD-induced changes in the CANTAB endpoints (change scores LSD minus placebo). The eleven subscales of the 5D-ASC (change score LSD minus placebo) and verbal IQ were entered as predictors. Statistical comparisons of all data were carried out on a significance level set at $p < 0.05$ (two-tailed).

Results

5D-ASC

There was a significant drug \times subscale interaction [$F_{(20,480)} = 15.10$, $p < 0.000001$] (Fig. 1), a significant main effect of subscale [$F_{(10,240)} = 16.62$, $p < 0.000001$] and a significant main effect of drug [$F_{(2,48)} = 85.06$, $p < 0.000001$]. Tukey post-hoc tests revealed that LSD significantly increased all subscale scores compared to Pla and Ket + LSD (all $p < 0.0001$) except for anxiety ($p > 0.7$). There were no significant differences between Pla and Ket + LSD in any subscale score (all $p > 0.9$).

Intra/Extra-Dimensional shift task

The stages completed did not differ between drug conditions [$F_{(2,48)} = 1.5$, $p > 0.2$; mean (SD) Pla: 8.84 (0.11), Ket + LSD: 8.76 (0.13), LSD: 8.68 (0.15)]. However, for number of errors adjusted, there was a significant effect of drug [$F_{(2,48)} = 4.9$, $p < 0.05$] with more errors in the LSD condition [mean (SD) = 19.96 (18.78), 95% CI 14.66–26.12] compared to Pla [mean (SD) = 13.96 (15.40), 95% CI 12.03–21.43, $p < 0.05$] and Ket + LSD [mean (SD) = 15.04 (16.22), 95% CI 12.66–22.56, $p < 0.05$] (Fig. 2A). To further investigate at which stage the errors occurred, we computed a repeated-measures ANOVA with stage and drug as within-subject factors. We found a significant drug \times stage interaction [$F_{(16,384)} = 1.81$, $p < 0.05$] (Fig. 2B), a significant main effect of stage [$F_{(8,192)} = 9.10$, $p < 0.00001$], and a significant main effect




Fig. 1. Subjective drug effects assessed with the 5D-ASC questionnaire 720 min after, the second, substance administration. LSD significantly increased all scale scores compared to Pla and Ket + LSD (all $p < 0.0001$, corrected), except for anxiety ($p > 0.7$, corrected). Data are expressed as mean + SEM. *** $p < 0.0001$, corrected.

of drug [$F_{(2,48)} = 4.50$, $p < 0.05$]. Tukey post-hoc tests revealed that LSD significantly increased the number of errors in stage 8 (EDS) [mean (SD) = 7.84 (10.51), 95% CI 8.20–14.62] compared to Pla [mean (SD) = 5.16 (8.97), 95% CI 7.00–12.48, $p < 0.0001$] and Ket + LSD [mean (SD) = 5.64 (8.90), 95% CI 6.95–12.38, $p < 0.01$], but not in any other stage compared to both, Pla and Ket + LSD (all $p > 0.9$). There were no significant differences in the number of errors in any stage between Pla and Ket + LSD ($p > 0.9$). For total latency, there was a significant drug \times stage interaction [$F_{(16,384)} = 1.94$, $p < 0.05$] (Fig. 2C), a significant main effect of stage [$F_{(8,192)} = 12.47$, $p < 0.00001$], and a significant main effect of drug [$F_{(2,48)} = 7.46$, $p < 0.01$]. Tukey post-hoc tests revealed that LSD significantly increased latency in stage 8 (EDS) [mean (SD) = 27.73 (20.00), 95% CI 15.62–27.83] compared to Pla [mean (SD) = 17.10 (13.19), 95% CI 10.30–18.35, $p < 0.0001$] and Ket + LSD [mean (SD) = 17.40 (13.38), 95% CI 10.45–18.62, $p < 0.0001$], but not in any other stage compared to Pla ($p > 0.6$) or Ket + LSD ($p > 0.7$). There were no significant differences in total latency scores in any stage between Pla and Ket + LSD (all $p > 0.9$).

Spatial working memory

For between errors, there was a significant drug \times stage interaction [$F_{(4,96)} = 4.59$, $p < 0.01$] (Fig. 3A), a significant main effect of drug [$F_{(2,48)} = 7.14$, $p < 0.01$], and a significant main effect of stage [$F_{(2,48)} = 34.88$, $p < 0.00001$]. Tukey post-hoc tests revealed that participants made significantly more between errors in the LSD condition [mean (SD) = 4.84 (7.41), 95% CI 5.79–10.31] than in the Pla condition when six boxes were presented [mean (SD) = 0.72 (1.72), 95% CI 1.34–2.39, $p < 0.01$]. Further, LSD significantly increased between errors [mean (SD) = 12.68 (12.03), 95% CI 9.40–16.74] when eight boxes were presented compared

to both Pla [mean (SD) = 5.52 (7.83), 95% CI 6.12–10.90, $p < 0.001$] and Ket + LSD [mean (SD) = 7.48 (8.36), 95% CI 6.53–11.63, $p < 0.001$]. There were no significant differences in the number of between errors between Pla and Ket + LSD at any stage (all $p > 0.6$). For within errors, there was no significant drug \times stage interaction [$F_{(4,96)} = 1.00$, $p > 0.4$] or main effect of drug [$F_{(2,48)} = 1.84$, $p > 0.1$] (Fig. 3B). However, we found a significant main effect of stage [$F_{(2,48)} = 5.09$, $p < 0.01$]. For the strategy score, there was a significant drug \times stage interaction [$F_{(4,96)} = 4.11$, $p < 0.01$] (Fig. 3C), a significant main effect of stage [$F_{(2,48)} = 205.50$, $p < 0.00001$], but no significant main effect of drug [$F_{(2,48)} = 1.48$, $p > 0.2$]. Tukey post-hoc tests revealed that the strategy score was increased (reflecting poor use of a strategy) under LSD [mean (SD) = 17.84 (3.88), 95% CI 3.03–5.40] compared to Pla [mean (SD) = 16.52 (3.72), 95% CI 2.91–5.18] and Ket + LSD [mean (SD) = 16.36 (4.02), 95% CI 3.14–5.60] when eight boxes were presented (both $p < 0.01$). There was no significant difference in the strategy scores between Pla and Ket + LSD at any stage (all $p > 0.9$).

Cambridge Gambling Task

For quality of decision-making, there was no significant drug \times risk ratio [$F_{(6,144)} = 0.38$, $p > 0.8$], interaction (Fig. 4A), and no main effects of drug [$F_{(2,48)} = 0.50$, $p > 0.6$] or risk ratio [$F_{(3,72)} = 1.93$, $p > 0.1$]. For risk taking (Fig. 4B), there was no significant drug \times risk ratio [$F_{(6,144)} = 1.04$, $p > 0.4$] interaction, and no significant main effect for drug [$F_{(2,48)} = 1.05$, $p > 0.3$]. However, there was a significant main effect of risk ratio [$F_{(3,72)} = 108.06$, $p < 0.000001$] for risk taking, indicating that participants made higher bets when the risk ratio was lower. For deliberation time, there was no significant drug \times risk ratio [$F_{(6,144)} = 1.31$, $p > 0.2$] interaction, but a significant main effect for drug [$F_{(2,48)} = 6.97$, $p < 0.01$]




Fig. 2. Intra/Extra-Dimensional shift task. Panel (A) displays the total number of errors adjusted for stages completed. LSD significantly increased the number of errors adjusted compared to Pla and Ket + LSD (both $p < 0.05$, corrected). Panel (B) displays the number of errors in each stage. LSD significantly increased the number of errors in the EDS stage compared to Pla ($p < 0.0001$, corrected) and Ket + LSD ($p < 0.01$, corrected). Panel (C) displays the total latency (mean time to reach a decision within individual stages). LSD significantly increased latency in the EDS stage compared to Pla and Ket + LSD (both $p < 0.0001$, corrected). Data are expressed as mean + SEM. * $p < 0.01$, corrected; *** $p < 0.0001$, corrected. IED stages: SD, simple discrimination; SR, simple reversal; CDA, compound discrimination adjacent; CDS, compound discrimination superimposed; CR, compound reversal; IDS, intra-dimensional shift; IDSR, intra-dimensional shift reversal; EDS, extra-dimensional shift; EDSR, extra-dimensional shift reversal.

(Fig. 4C), and a significant main effect for risk ratio [$F_{(3,72)} = 4.96$, $p < 0.01$]. Tukey post-hoc tests revealed that LSD significantly increased deliberation time [mean (SD) = 2.15 (1.19), 95% CI 1.66–2.64] compared to Pla [mean (SD) = 1.74 (0.74), 95% CI 1.43–2.04] and Ket + LSD [mean (SD) = 1.71 (0.81), 95% CI 1.39–2.04] (both $p < 0.01$) but there was no significant difference between Pla and Ket + LSD ($p > 0.9$). Further, participants needed significantly more time for making their choice when the ratio was 8:2 or 6:4 (both $p < 0.05$) compared to the ratio 9:1. No other significant differences between risk ratios were found (all $p > 0.8$).

Multiple regression analysis for 5D-ASC scales, and verbal IQ predicting LSD-induced changes in CANTAB outcome variables

5D-ASC scales and verbal IQ were entered as predictors of significant LSD-induced changes in CANTAB outcome variables (IED: EDS errors, Latency EDS stage; SWM: Between errors 6 boxes, Between errors 8 boxes, Strategy 8 boxes; CGT: Deliberation time) in separate multiple regression models. None of the models was significant. There was a trend in the regression equation for Latency EDS stage [$F_{(12,12)} = 2.648$, $p < 0.06$], with an $R^2 = 0.726$. However, none of the individual predictors reached significance (all $p > 0.05$). Detailed results of the multiple linear regression analyses are presented in the online Supplementary material Tables S1–S3.

Discussion

Trans-diagnostic deficits in cognitive abilities are highly prevalent in psychiatric and neurological disorders, but are insufficiently improved by current treatment approaches (Millan *et al.*, 2012). The current study closes major knowledge gaps in the field via the administration of LSD together with a 5-HT_{2A} receptor antagonist and the application of standardized and computerized

cognitive tasks that capture the most relevant cognitive domains impaired in psychiatric disorders (Jessen *et al.*, 2019). We show that (I) acutely administered LSD significantly impaired executive functions and working memory compared to placebo, (II) risk-based decision-making was unaffected by LSD, and (III) LSD-induced cognitive deficits and subjective symptoms were dependent on 5-HT_{2A} receptor stimulation.

LSD impairs cognitive flexibility and executive functions on the Intra/Extra-Dimensional shift task

LSD led to a significant increase in error rates and increased latency in the EDS stage of the IED task compared to placebo. These impairments were normalized in the Ket + LSD condition. Impairments in the EDS stage are interpreted as signs of preservation of a previously established attentional set (Elliott *et al.*, 1995). Extradimensional shifting requires being able to inhibit the previously established attentional set and shift attention between stimulus dimensions. Therefore, impairments in EDS are interpreted as reduced cognitive flexibility (Chamberlain *et al.*, 2007). Processes that may underlie this LSD-induced decrease in cognitive flexibility are deficits in executive functions, in particular increased susceptibility to distraction from task-irrelevant stimuli (Jazbec *et al.*, 2007). This interpretation is supported by previous studies in healthy humans which have shown that psilocybin, a structurally related serotonergic hallucinogen and 5-HT_{2A} receptor agonist, led to a significant decline of correct detection and an increase of false alarm in the AX continuous performance test (Umbricht *et al.*, 2003) and to a significant reduction in attentional tracking ability on a multiple-object tracking task, an effect attenuated by ketanserin (Carter *et al.*, 2007). The authors of the later study suggest that the impaired attentional performance under psilocybin may reflect a reduced ability to suppress or ignore distracting stimuli rather than reduced attentional capacity *per se*. This interpretation may also




Fig. 3. Spatial Working Memory task. Panel (A) displays between errors. LSD significantly increased the number of between errors when six boxes were presented compared to Pla ($p < 0.01$, corrected). When eight boxes were presented, LSD significantly increased between errors compared to Pla and Ket + LSD (both $p < 0.001$, corrected). Panel (B) displays within errors. There were no significant drug effects for the number of within errors. Panel (C) displays the strategy scores. LSD reduced the use of an efficient search strategy when eight boxes were presented compared to Pla and Ket + LSD (both $p < 0.01$, corrected). Data are expressed as mean + SEM. * $p < 0.01$, corrected; ** $p < 0.001$, corrected.

explain seemingly contradictory findings reporting increases in psychological flexibility under the influence of other psychedelic substances (Kuypers *et al.*, 2016). Here, participants were instructed to provide alternative interpretations of the presented stimulus material. However, the applied tasks did not require the suppression of distracting elements which may explain the differing results. In contrast to our current finding, an early study with LSD found no significant change in performance on the Wisconsin Card Sorting Test (Primac *et al.*, 1957), of which the IED is the computerized analog. It seems likely that this previous study was not able to detect LSD-induced effects due to the small sample size ($n = 10$). Importantly, LSD-induced impairments in cognitive flexibility and executive functions were normalized by ketanserin, therefore pinpointing the crucial role of the 5-HT_{2A} receptor in these cognitive functions. While speculative, a reduced ability to ignore stimuli under the influence of psychedelics may be important for psychedelic-assisted therapeutic approaches. It is possible that being unable to ignore otherwise suppressed thoughts may promote a confrontation with and deeper understanding of problems that patients face and therefore contribute to the potential clinical efficacy of psychedelic substances.

LSD impairs executive functions and working memory on the Spatial Working Memory task

LSD compared to placebo led to a significant increase of between errors and decreased use of strategy in the SWM. An increase in between errors represents a deficit in working memory, since participants revisited boxes even though a token had already been found within the box. Deficits in strategy represent impairments in executive functions. Importantly, these effects were only present when the cognitive load was high. These results are in line with previous studies investigating the effects of other psychedelic 5-HT_{2A} agonists on spatial working memory. Psilocybin has been shown to dose-dependently impair performance on a different SWM (Wittmann *et al.*, 2007). Furthermore, ayahuasca acutely

impaired working memory (Bouso *et al.*, 2013). Similarly to results obtained on the IED, pre-treatment with ketanserin normalized LSD-induced working memory and executive function deficits on the SWM in the current study. No treatment effect was found for within-errors. Although the within-error rate increased when more boxes were presented, the error rate was generally very low regardless of the treatment condition. Therefore, potential treatment effects may only become apparent if cognitive load were even further increased.

The role of the 5-HT_{2A} receptor in LSD-induced cognitive impairments

On both, the IED and the SWM task, blocking the 5-HT_{2A} receptor with ketanserin prevented LSD-induced cognitive deficits, therefore pointing to the importance of this receptor system in working memory and executive functions. This result is in line with a recent computational study indicating that 5-HT_{2A} receptors contribute to SWM (Cano-Colino *et al.*, 2014). The hippocampus is particularly involved in spatial memory and has moderate to high levels of 5-HT_{2A} receptors (Dwivedi and Pandey, 1998; Naghdi and Harooni, 2005). Furthermore, the prefrontal cortex (PFC) is implicated in higher-order executive tasks such as working memory, attention, and executive function (Millan *et al.*, 2012). This is corroborated by studies showing spatial working memory impairments and poor use of strategy in patients with lesions of the frontal lobe on the SWM (Owen *et al.*, 1990, 1995, 1996). Further, switching attention between stimulus dimensions such as in the EDS stage of the IED involves the ventrolateral PFC (Dias *et al.*, 1996; Hampshire and Owen, 2006; Morris *et al.*, 2016; Vaghi *et al.*, 2017). The PFC is linked to the parietal cortex, which exerts a modulatory influence on attention and working memory (Millan *et al.*, 2012). Involvement of these structures in deficits in working memory and executive function in the current study is conceivable given that participants under LSD showed a disintegration of functional




Fig. 4. Cambridge Gambling Task. No significant effects of the drug were found for (A) quality of decision-making or (B) risk taking but for (C) deliberation time in seconds. LSD increased deliberation time compared to Pla and Ket + LSD (both $p < 0.01$, corrected). Data are expressed as mean + SEM. * $p < 0.01$, corrected.

connectivity in these brain networks (Preller *et al.*, 2018a). Both structures have a particular high density of 5-HT_{2A} receptors, and they exert top-down modulatory influence on subcortical regions including the hippocampus (Pompeiano *et al.*, 1994). Clinical evidence corroborates the current results pinpointing the importance of the 5-HT_{2A} receptor in cognitive abilities: Atypical antipsychotics, which have 5-HT_{2A} receptor antagonistic properties, have been shown to be advantageous for treating cognitive impairments in schizophrenia compared to classic antipsychotics (Meltzer *et al.*, 2012). There are qualitative similarities between hallucinogen-induced alterations in information processing and the symptoms of an early phase of schizophrenic psychoses (Geyer and Vollenweider, 2008). Specifically, sensorimotor gating as indexed by prepulse inhibition (PPI) is impaired in patients with schizophrenia and related to cognitive deficits (Braff *et al.*, 2001). LSD and psilocybin disrupt PPI in healthy subjects, an effect that was also correlated with impairments of sustained attention in healthy humans (Gouzoulis-Mayfrank *et al.*, 1998; Quednow *et al.*, 2012; Schmid *et al.*, 2015; Vollenweider *et al.*, 2007). Importantly, it has been shown that the disruptions of PPI induced by psilocybin in humans and LSD in rats are reversed by 5-HT_{2A} receptor antagonists (Halberstadt and Geyer, 2010; Ouagazzal *et al.*, 2001; Quednow *et al.*, 2012).

Together these results suggest that the 5-HT_{2A} receptor system may be a promising target in the treatment of trans-diagnostic impairments in working memory and executive functions. This is also corroborated by data from animal and human studies suggesting that selective 5-HT_{2A} receptor modulators targeting distinct signaling pathways could be possible therapeutic approaches to improve cognitive impairments (Zhang and Stackman, 2015; Švob Štrac *et al.*, 2016). For example, intrahippocampal injections of the 5HT_{2A} antagonist ritanserin increased spatial learning and memory in rats (Naghdi and Harooni, 2005) and treatment with 5-HT_{2A} antagonist EMD 281014 improved working memory in non-human primates (Terry *et al.*, 2005). Although 5-HT_{2A} antagonism was reported to

improve cognition in schizophrenia (Roth *et al.*, 2004), it has also been reported that atypical antipsychotics with lower 5-HT_{2A} antagonistic affinity have higher efficacy in improving cognitive performance than drugs with higher affinity (Tyson *et al.*, 2006). Therefore, further studies with 5-HT_{2A} agonists and antagonists are needed to elucidate the involvement of this receptor subtype in different cognitive functions in patient populations.

LSD does not affect risk-based decision-making on the Cambridge Gambling Task

Interestingly, in the CGT, LSD did not influence the quality of decision-making and risk taking. Even though previous evidence indicates that the 5-HT system may be involved in the quality of decision-making (Rogers *et al.*, 1999), our current results indicate that these cognitive domains may not be modulated by 5-HT_{2A} receptor signaling. This is in line with a recent study that showed that psilocybin had no effect on moral decision-making (Pokorny *et al.*, 2017). Furthermore, this result supports previous reports that associate risk-based decision-making behavior with dopaminergic signaling, whereas the serotonin system has been suggested to play a role in the regulation of cognitive biases, and therefore the appraisal of reinforcers when selecting between actions, in particular in a learning context (Rogers, 2011). The CGT, however, is not relying on learning, and risk-based decision-making on the CGT may therefore not be sensitive to alterations in 5-HT_{2A} receptor signaling. Yet, LSD also has affinity for dopamine receptors and animal studies have reported a first 5-HT_{2A} receptor mediated and a second D2 receptor mediated phase of action (Marona-Lewicka and Nichols, 2007; Marona-Lewicka *et al.*, 2005). However, the involvement of the dopaminergic system in this study is unlikely as pretreatment with ketanserin normalized the LSD-induced effects not only in the CANTAB tasks 220 min after drug intake but also the retrospective rated psychological effects measured with the 5D-ASC. Therefore, the present results indicate that the effects of LSD in humans are primarily

mediated via 5-HT_{2A} receptor activation. This is in line with recent reports, that LSD in humans increased the levels of prolactin and cortisol, which are markers for serotonergic drug activity (Schmid *et al.*, 2015; Seifritz *et al.*, 1996; Sommers *et al.*, 1994). However, it is possible that higher doses of LSD are needed to modulate dopaminergic activity and potentially induce alterations in risk-based decision-making.

LSD-induced cognitive impairments are not predicted by subjective effects or verbal IQ

Regression analyses to predict LSD-induced cognitive impairments testing the impact of subjective effects and IQ were not significant. Importantly, this suggests that cognitive processes under LSD are not confounded by psychedelic effects, in particular visual inaccuracies or disturbances. Furthermore, LSD-induced impairments were not related to individuals' IQ, suggesting that 5-HT_{2A} receptor stimulation by LSD impaired working memory and executive functions independently of general intelligence.

Limitations

Previous studies have shown that the selective 5-HT_{2A} receptor antagonist ketanserin is suitable for studying the role of 5-HT_{2A} receptors in human performance and to investigate the specific contribution of the 5-HT_{2A} receptor to effects of psychedelic drugs (Carter *et al.*, 2007; Kometer *et al.*, 2012; Liechti *et al.*, 2000; Quednow *et al.*, 2012; Vollenweider *et al.*, 1998; Preller *et al.*, 2017). A limitation of the present study is the lack of a fourth drug condition investigating the effect of ketanserin alone. However, previous studies have shown that ketanserin administered in the same dose (40 mg) as used in this study and even at a higher dose (50 mg) neither led to any significant differences in subjective drug effects assessed with the 5D-ASC (Carter *et al.*, 2007; Kometer *et al.*, 2012, both 50 mg ketanserin), nor to performance changes in cognitive tasks such as a different SWM (Carter *et al.*, 2005, 50 mg ketanserin), or the Stroop task (Quednow *et al.*, 2012, 40 mg ketanserin) in healthy volunteers. Furthermore, to be able to comprehensively investigate the role of the 5-HT_{2A} receptor in human cognition, future research will additionally need to focus on effects of other 5-HT_{2A} agonists, such as the non-hallucinogenic drug lisuride, on cognitive processes.

Conclusion

In conclusion, the present study pinpoints the role of the 5-HT_{2A} receptor in cognitive processes, in particular executive functions, cognitive flexibility, and spatial working memory. However, risk-based decision-making outside a learning context was unaffected by LSD and is therefore potentially not mediated by the 5-HT_{2A} receptor. Blocking the 5-HT_{2A} receptor by ketanserin normalized both LSD-induced cognitive impairments and subjective drug effects. As altered 5-HT_{2A} receptor density and cognitive dysfunctions are found in several psychiatric disorders such as in schizophrenia, autism, and obsessive-compulsive disorder (Millan *et al.*, 2012), this receptor subtype represents a promising target to help understand the neuropharmacological basis of cognitive processes and to improve treatment in affected patients.

Supplementary material. The supplementary material for this article can be found at <https://doi.org/10.1017/S0033291719002393>

Acknowledgements. We thank Amanda Planzer, Jan Flemming, and Rainer Krähenmann for their assistance in data collection.

Financial support. Funding for this study was provided by Swiss Neuromatrix Foundation (FX.V., grant number 2015–2056) and Heffter Research Institute (FX.V., grant number 1-190413); both foundations had no further role in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication.

Conflict of interest. None.

Ethical standards. The authors assert that all procedures contributing to this work comply with the ethical standards of the relevant national and institutional committees on human experimentation and with the Helsinki Declaration of 1975, as revised in 2008.

References

- Bhagwagar Z, Hinz R, Taylor M, Fancy S, Cowen P and Grasby P (2006) Increased 5-HT(2A) receptor binding in euthymic, medication-free patients recovered from depression: a positron emission study with (11)C-MDL 100907. *The American Journal of Psychiatry* **163**, 1580–1587.
- Bousso JC, Fabregas JM, Antonijoan RM, Rodriguez-Fornells A and Riba J (2013) Acute effects of ayahuasca on neuropsychological performance: differences in executive function between experienced and occasional users. *Psychopharmacology* **230**, 415–424.
- Braff DL, Geyer MA and Swardlow NR (2001) Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. *Psychopharmacology* **156**, 234–258.
- Cano-Colino M, Almeida R, Gomez-Cabrero D, Artigas F and Compte A (2014) Serotonin regulates performance nonmonotonically in a spatial working memory network. *Cerebral Cortex (New York, NY: 1991)* **24**, 2449–2463.
- Carhart-Harris RL, Kaelen M, Bolstridge M, Williams TM, Williams LT, Underwood R, Feilding A and Nutt DJ (2016) The paradoxical psychological effects of lysergic acid diethylamide (LSD). *Psychological Medicine* **46**, 1379–1390.
- Carter OL, Burr DC, Pettigrew JD, Wallis GM, Hasler F and Vollenweider FX (2005) Using psilocybin to investigate the relationship between attention, working memory, and the serotonin 1A and 2A receptors. *Journal of Cognitive Neuroscience* **17**, 1497–1508.
- Carter OL, Hasler F, Pettigrew JD, Wallis GM, Liu GB and Vollenweider FX (2007) Psilocybin links binocular rivalry switch rate to attention and subjective arousal levels in humans. *Psychopharmacology* **195**, 415–424.
- Chamberlain SR, Fineberg NA, Menzies LA, Blackwell AD, Bullmore ET, Robbins TW and Sahakian BJ (2007) Impaired cognitive flexibility and motor inhibition in unaffected first-degree relatives of patients with obsessive-compulsive disorder. *The American Journal of Psychiatry* **164**, 335–338.
- Claesdotter E, Cervin M, Åkerlund S, Råstam M and Lindvall M (2018) The effects of ADHD on cognitive performance. *Nordic Journal of Psychiatry* **72**, 158–163.
- Clark L, Bechara A, Damasio H, Aitken MRF, Sahakian BJ and Robbins TW (2008) Differential effects of insular and ventromedial prefrontal cortex lesions on risky decision-making. *Brain* **131**, 1311–1322.
- Désaméricq G, Schurhoff F, Meary A, Szöke A, Macquin-Mavier I, Bachoud-Lévi AC and Maison P (2014) Long-term neurocognitive effects of antipsychotics in schizophrenia: a network meta-analysis. *European Journal of Clinical Pharmacology* **70**, 127–134.
- Dias R, Robbins TW and Roberts AC (1996) Dissociation in prefrontal cortex of affective and attentional shifts. *Nature* **380**, 69–72.
- Dittrich A (1998) The standardized psychometric assessment of altered states of consciousness (ASCs) in humans. *Pharmacopsychiatry* **31**(Suppl. 2), 80–84.
- Dwivedi Y and Pandey GN (1998) Quantitation of 5HT_{2A} receptor mRNA in human postmortem brain using competitive RT-PCR. *Neuroreport* **9**, 3761–3765.

- Elliott R, McKenna PJ, Robbins TW and Sahakian BJ (1995) Neuropsychological evidence for frontostriatal dysfunction in schizophrenia. *Psychological Medicine* 25, 619–630.
- Geyer MA and Vollenweider FX (2008) Serotonin research: contributions to understanding psychoses. *Trends in Pharmacological Sciences* 29, 445–453.
- Gouzoulis-Mayfrank E, Heekeren K, Thelen B, Lindenblatt H, Kovar KA, Sass H and Geyer MA (1998) Effects of the hallucinogen psilocybin on habituation and prepulse inhibition of the startle reflex in humans. *Behavioural Pharmacology* 9, 561–566.
- Halberstadt AL and Geyer MA (2010) LSD but not lisuride disrupts prepulse inhibition in rats by activating the 5-HT(2A) receptor. *Psychopharmacology* 208, 179–189.
- Hampshire A and Owen AM (2006) Fractionating attentional control using event-related fMRI. *Cerebral Cortex (New York, NY: 1991)* 16, 1679–1689.
- Hill SK, Bishop JR, Palumbo D and Sweeney JA (2010) Effect of second-generation antipsychotics on cognition: current issues and future challenges. *Expert Review of Neurotherapeutics* 10, 43–57.
- Jagust W (2018) Imaging the evolution and pathophysiology of Alzheimer disease. *Nature Reviews. Neuroscience* 19, 687–700.
- Jazbec S, Pantelis C, Robbins T, Weickert T, Weinberger DR and Goldberg TE (2007) Intra-dimensional/extra-dimensional set-shifting performance in schizophrenia: impact of distractors. *Schizophrenia Research* 89, 339–349.
- Jessen K, Mandl RCW, Fagerlund B, Bojesen KB, Raghava JM, Obaid HG, Jensen MB, Johansen LB, Nielsen MØ, Pantelis C, Rostrup E, Glenthøj BY and Ebdrup BH (2019) Patterns of cortical structures and cognition in antipsychotic-naïve patients with first-episode schizophrenia: a partial least squares correlation analysis. *Biological Psychiatry. Cognitive Neuroscience and Neuroimaging* 4, 444–453.
- Komater M, Schmidt A, Bachmann R, Studerus E, Seifritz E and Vollenweider FX (2012) Psilocybin biases facial recognition, goal-directed behavior, and mood state toward positive relative to negative emotions through different serotonergic subreceptors. *Biological Psychiatry* 72, 898–906.
- Kraehenmann R, Pokorny D, Aicher H, Preller KH, Pokorny T, Bosch OG, Seifritz E and Vollenweider FX (2017) LSD increases primary process thinking via serotonin 2A receptor activation. *Frontiers in Pharmacology* 8, 814.
- Kuypers KPC, Riba J, de La Fuente Revenga M, Barker S, Theunissen EL and Ramaekers JG (2016) Ayahuasca enhances creative divergent thinking while decreasing conventional convergent thinking. *Psychopharmacology* 233, 3395–3403.
- Lehr S (2005) *Manual zum MWT-B*. Spitta-Verl.: Balingen.
- Liechti ME, Saur MR, Gamma A, Hell D and Vollenweider FX (2000) Psychological and physiological effects of MDMA ('ecstasy') after pretreatment with the 5-HT(2) antagonist ketanserin in healthy humans. *Neuropsychopharmacology* 23, 396–404.
- Marona-Lewicka D and Nichols DE (2007) Further evidence that the delayed temporal dopaminergic effects of LSD are mediated by a mechanism different than the first temporal phase of action. *Pharmacology, Biochemistry, and Behavior* 87, 453–461.
- Marona-Lewicka D, Thisted RA and Nichols DE (2005) Distinct temporal phases in the behavioral pharmacology of LSD: dopamine D2 receptor-mediated effects in the rat and implications for psychosis. *Psychopharmacology* 180, 427–435.
- Meltzer HY, Massey BW and Horiguchi M (2012) Serotonin receptors as targets for drugs useful to treat psychosis and cognitive impairment in schizophrenia. *Current Pharmaceutical Biotechnology* 13, 1572–1586.
- Millan MJ, Agid Y, Brune M, Bullmore ET, Carter CS, Clayton NS, Connor R, Davis S, Deakin B, DeRubeis RJ, Dubois B, Geyer MA, Goodwin GM, Gorwood P, Jay TM, Joels M, Mansuy IM, Meyer-Lindenberg A, Murphy D, Rolls E, Saletu B, Spedding M, Sweeney J, Whittington M and Young LJ (2012) Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy. *Nature Reviews. Drug Discovery* 11, 141–168.
- Morris LS, Kundu P, Dowell N, Mechelmans DJ, Favre P, Irvine MA, Robbins TW, Daw N, Bullmore ET, Harrison NA and Voon V (2016) Fronto-striatal organization: defining functional and microstructural substrates of behavioural flexibility. *Cortex* 74, 118–133.
- Naghdhi N and Harooni HE (2005) The effect of intrahippocampal injections of ritanserin (5HT_{2A/2C} antagonist) and granisetron (5HT₃ antagonist) on learning as assessed in the spatial version of the water maze. *Behavioural Brain Research* 157, 205–210.
- Ouagazzal A, Grottick AJ, Moreau J and Higgins GA (2001) Effect of LSD on prepulse inhibition and spontaneous behavior in the rat. A pharmacological analysis and comparison between two rat strains. *Neuropsychopharmacology* 25, 565–575.
- Owen AM, Downes JJ, Sahakian BJ, Polkey CE and Robbins TW (1990) Planning and spatial working memory following frontal lobe lesions in man. *Neuropsychologia* 28, 1021–1034.
- Owen AM, Roberts AC, Polkey CE, Sahakian BJ and Robbins TW (1991) Extra-dimensional versus intra-dimensional set shifting performance following frontal lobe excisions, temporal lobe excisions or amygdalo-hippocampectomy in man. *Neuropsychologia* 29, 993–1006.
- Owen AM, Roberts AC, Hodges JR, Summers BA, Polkey CE and Robbins TW (1993) Contrasting mechanisms of impaired attentional set-shifting in patients with frontal lobe damage or Parkinson's disease. *Brain* 116, 1159–1175.
- Owen AM, Sahakian BJ, Semple J, Polkey CE and Robbins TW (1995) Visuo-spatial short-term recognition memory and learning after temporal lobe excisions, frontal lobe excisions or amygdalo-hippocampectomy in man. *Neuropsychologia* 33, 1–24.
- Owen AM, Morris RG, Sahakian BJ, Polkey CE and Robbins TW (1996) Double dissociations of memory and executive functions in working memory tasks following frontal lobe excisions, temporal lobe excisions or amygdalo-hippocampectomy in man. *Brain* 119, 1597–1615.
- Pantelis C, Wood SJ, Proffitt TM, Testa R, Mahony K, Brewer WJ, Buchanan J-A, Velakoulis D and McGorry PD (2009) Attentional set-shifting ability in first-episode and established schizophrenia: relationship to working memory. *Schizophrenia Research* 112, 104–113.
- Perani D, Garibotto V, Gorini A, Moresco RM, Henin M, Panzacchi A, Matarrese M, Carpinelli A, Bellodi L and Fazio F (2008) In vivo PET study of 5HT(2A) serotonin and D(2) dopamine dysfunction in drug-naïve obsessive-compulsive disorder. *NeuroImage* 42, 306–314.
- Pokorny T, Preller KH, Komater M, Dziobek I and Vollenweider FX (2017) Effect of Psilocybin on Empathy and Moral Decision-Making. *The International Journal of Neuropsychopharmacology* 20, 747–757.
- Pompeiano M, Palacios JM and Mengod G (1994) Distribution of the serotonin 5-HT₂ receptor family mRNAs: comparison between 5-HT_{2A} and 5-HT_{2C} receptors. *Brain Research. Molecular Brain Research* 23, 163–178.
- Preller KH, Herdener M, Pokorny T, Planzer A, Kraehenmann R, Stämpfli P, Liechti ME, Seifritz E and Vollenweider FX (2017) The fabric of meaning and subjective effects in LSD-induced states depend on serotonin 2A receptor activation. *Current Biology* 27, 451–457.
- Preller KH, Burt JB, Ji JL, Schiefer CH, Adkinson BD, Stämpfli P, Seifritz E, Repovs G, Krystal JH, Murray JD, Vollenweider FX and Anticevic A (2018a) Changes in global and thalamic brain connectivity in LSD-induced altered states of consciousness are attributable to the 5-HT_{2A} receptor. *eLife* 7, e35082.
- Preller KH, Schilbach L, Pokorny T, Flemming J, Seifritz E and Vollenweider FX (2018b) Role of the 5-HT_{2A} receptor in self- and other-initiated social interaction in LSD-induced states - a pharmacological fMRI study. *The Journal of Neuroscience* 38, 3603–3611.
- Primac DW, Mirsky AF and Rosvold HE (1957) Effects of centrally acting drugs on two tests of brain damage. *A.M.A. Archives of Neurology and Psychiatry* 77, 328–332.
- Quednow BB, Komater M, Geyer MA and Vollenweider FX (2012) Psilocybin-induced deficits in automatic and controlled inhibition are attenuated by ketanserin in healthy human volunteers. *Neuropsychopharmacology* 37, 630–640.
- Rogers RD (2011) The roles of dopamine and serotonin in decision making: evidence from pharmacological experiments in humans. *Neuropsychopharmacology* 36, 114–132.
- Rogers RD, Everitt BJ, Baldacchino A, Blackshaw AJ, Swainson R, Wynne K, Baker NB, Hunter J, Carthy T, Booker E, London M,

- Deakin JF, Sahakian BJ and Robbins TW (1999) Dissociable deficits in the decision-making cognition of chronic amphetamine abusers, opiate abusers, patients with focal damage to prefrontal cortex, and tryptophan-depleted normal volunteers: evidence for monoaminergic mechanisms. *Neuropsychopharmacology* **20**, 322–339.
- Roth BL, Hanizavareh SM and Blum AE (2004) Serotonin receptors represent highly favorable molecular targets for cognitive enhancement in schizophrenia and other disorders. *Psychopharmacology* **174**, 17–24.
- Schmid Y, Enzler F, Gasser P, Grouzmann E, Preller KH, Vollenweider FX, Brenneisen R, Muller F, Borgwardt S and Liechti ME (2015) Acute effects of lysergic acid diethylamide in healthy subjects. *Biological Psychiatry* **78**, 544–553.
- Seifritz E, Baumann P, Muller MJ, Annen O, Amey M, Hemmeter U, Hatzinger M, Chardon F and Holsboer-Trachsler E (1996) Neuroendocrine effects of a 20-mg citalopram infusion in healthy males. A placebo-controlled evaluation of citalopram as 5-HT function probe. *Neuropsychopharmacology* **14**, 253–263.
- Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R and Dunbar GC (1998) The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. *The Journal of Clinical Psychiatry* **59**(suppl. 20), 22–33.
- Sommers DK, van Wyk M and Snyman JR (1994) Dexfenfluramine-induced prolactin release as an index of central synaptosomal 5-hydroxytryptamine during treatment with fluoxetine. *European Journal of Clinical Pharmacology* **46**, 441–444.
- Studerus E, Gamma A and Vollenweider FX (2010) Psychometric evaluation of the altered states of consciousness rating scale (OAV). *PLoS ONE* **5**, e12412.
- Švob Štrac D, Pivac N and Mück-Šeler D (2016) The serotonergic system and cognitive function. *Translational Neuroscience* **7**, 35–49.
- Talvik-Lotfi M, Nyberg S, Nordström AL, Ito H, Halldin C, Brunner F and Farde L (2000) High 5HT_{2A} receptor occupancy in M100907-treated schizophrenic patients. *Psychopharmacology* **148**, 400–403.
- Terry AV, Buccafusco JJ and Bartoszyk GD (2005) Selective serotonin 5-HT_{2A} receptor antagonist EMD 281014 improves delayed matching performance in young and aged rhesus monkeys. *Psychopharmacology* **179**, 725–732.
- Tyson PJ, Laws KR, Flowers KA, Tyson A and Mortimer AM (2006) Cognitive function and social abilities in patients with schizophrenia: relationship with atypical antipsychotics. *Psychiatry and Clinical Neurosciences* **60**, 473–479.
- Umbricht D, Vollenweider FX, Schmid L, Grubel C, Skrabo A, Huber T and Koller R (2003) Effects of the 5-HT_{2A} agonist psilocybin on mismatch negativity generation and AX-continuous performance task: implications for the neuropharmacology of cognitive deficits in schizophrenia. *Neuropsychopharmacology* **28**, 170–181.
- Vaghi MM, Vértes PE, Kitzbichler MG, Apergis-Schoute AM, van der Flier FE, Fineberg NA, Sule A, Zaman R, Voon V, Kundu P, Bullmore ET and Robbins TW (2017) Specific frontostriatal circuits for impaired cognitive flexibility and goal-directed planning in obsessive-compulsive disorder: evidence from resting-state functional connectivity. *Biological Psychiatry* **81**, 708–717.
- Vollenweider FX, Vollenweider-Scherpenhuyzen MF, Babler A, Vogel H and Hell D (1998) Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. *Neuroreport* **9**, 3897–3902.
- Vollenweider FX, Csomor PA, Knappe B, Geyer MA and Quednow BB (2007) The effects of the preferential 5-HT_{2A} agonist psilocybin on pre-pulse inhibition of startle in healthy human volunteers depend on interstimulus interval. *Neuropsychopharmacology* **32**, 1876–1887.
- Wang AM, Pradhan S, Coughlin JM, Trivedi A, DuBois SL, Crawford JL, Sedlak TW, Nucifora FC, Nestadt G, Nucifora LG, Schretlen DJ, Sawa A and Barker PB (2019) Assessing brain metabolism with 7-T proton magnetic resonance spectroscopy in patients with first-episode psychosis. *JAMA Psychiatry* **76**, 314–323.
- Wittmann M, Carter O, Hasler F, Cahn BR, Grimberg U, Spring P, Hell D, Flohr H and Vollenweider FX (2007) Effects of psilocybin on time perception and temporal control of behaviour in humans. *Journal of Psychopharmacology* **21**, 50–64.
- Wunderli MD, Vonmoos M, Niedecker SM, Hulka LM, Preller KH, Baumgartner MR, Kraemer T, Seifritz E, Schaub MP, Eich-Höchli D and Quednow BB (2016) Cognitive and emotional impairments in adults with attention-deficit/hyperactivity disorder and cocaine use. *Drug and Alcohol Dependence* **163**, 92–99.
- Zhang G and Stackman RW (2015) The role of serotonin 5-HT_{2A} receptors in memory and cognition. *Frontiers in Pharmacology* **6**, 225.